Prophylactic Amotosalen-Treated Donor T-Cells Prevent Late CMV Infection in Allogeneic Bone Marrow Transplantation

The study investigated the use of amotosalen-treated donor T-cells in allogeneic bone marrow transplantation (BMT) to prevent late cytomegalovirus (CMV) infection without causing graft-versus-host disease (GvHD). Using a mouse model, researchers found that recipients of amotosalen-treated splenocytes did not develop GvHD and showed significantly improved immune responses to CMV infection compared to those receiving untreated splenocytes. The treated T-cells expanded rapidly in response to infection, exhibited strong anti-viral activity, and contributed to better hematopoietic engraftment and immune reconstitution. This approach demonstrated potential as a safe and effective method for enhancing anti-viral immunity in BMT recipients.